CD19 antibody inebilizumab prevents relapses in IgG4-associated…

medicine Friday, November 15, 2024 Boston – The CD19 antibody inebilizumab, already approved to treat another rare autoimmune disease, reduced the frequency of disease flare-ups by more than 90% in a phase 3 study in